Monobody
Based Therapeutic Drugs Market - Global Industry Insights, Trends, Outlook,
and Opportunity Analysis, 2018-2026
Monobodies are synthetic binding
proteins in which fibronectin type III domain (FN3) is used as a molecular
scaffold. Monobodies are robust alternative to antibodies to create
target-binding proteins. The term monobody was devised by Koide group in 1998.
Monobody belong to a class called antibody mimics aiming to overcome the
shortcomings of natural antibody. A major advantage of monobody is that it can
be used as genetically encoded intracellular inhibitors. Adnexus (now a part of
Bristol-Myers Squibb), uses monobody technology to inhibit tumor angiogenesis
since 2007.
Monobody – a technology with great
potential in Cancer Treatment
Monobody is a technology which
has great potential in the treatment of cancer. Monobody is independent of
their environment and can be used as genetically encoded inhibitors. When a
monobody binds to a protein then it work as an inhibitor of that protein.
Pegdinetanib, also known as
Adnectin, is an antagonist of vascular endothelial growth factor receptor 2 has
entered in clinical trial II for the treatment of glioblastoma. Adnectins is
based on 10th fibronectin type III domain designed to bind with high affinity
and specificity to relevant targets. There are three solvent accessible loops
(BC, DE, and FG) which are responsible for binding. Various monobody proteins
have been developed for clinical efficacy against cancer and infections. The market of monobody will be high in
developed region like America because of availability of advance medical
technology, good medical facilities and medical infrastructure.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/43
Success of therapeutic antibodies
has sparked a growing interest to create molecules that bind to the target
molecule specifically and efficiently. A common alternative process is that the
libraries of monobody being constructed which can be obtained by capturing natural
diversity of an antibody.
Research in the field of Monobody
Researchers at the University of
Illinois, Chicago identified a monobody, NS1, which can block oncogene
activity. 30% of all cancers are due to RAS mutation. RAS mutation is also
found in 90% of pancreatic cancers and frequently occurs in colon cancer, lung
cancer and melanoma. The NS1 monobody bind to RAS protein molecule and inhibits
its oncogenic activity.
Monobody – a better alternative
Antibodies are successful tools
used in diagnostics, purification, and therapeutics. Antibodies have their
limitations also like high product cost and low stability. Alternative tools
based on nucleic acid (aptamers), polypeptides (engineered binding proteins)
and inorganic matrices have received attention recently. With increasing
research activities for drug development in cancer, more information would be
gathered with respect to monobodies too. Because of high specificity and
affinity monobodies have potential and can be used in organ transplant in near
future and can affect the antibodies market. Successful outcomes will boost
investors to develop this technology and address the unmet need of cancer
patients undergoing antibody therapy. Use of monobodies as therapeutic drug
improves patient situation and hence companies are striving to develop
monobodies to be used as therapeutic drugs in the treatment of cancer.
Browse Research
Report: https://www.coherentmarketinsights.com/ongoing-insight/monobody-based-therapeutic-drugs-market-43
Introduction of monobody will
have a major impact in developed regions
The rate of organ transplantation
in the U.S. is high. According to National Kidney Foundation, there are
currently 121,678 people waiting for organ transplant in the U.S of which
100,791 await kidney transplant. Monoclonal antibodies are used in successful
transplant and are administered before transplant. It will become one of the
major drivers for monobody based therapeutic drugs market. Monobody technology
requires high investment to commercialize. The advancement of monobody
technology to treat cancer will have an impact on the existing antibody
treatment technologies.
Key Developments
Research and development in use
of monobody-based therapies is expected to boost the market growth. For
instance, in August 2019, researchers from The University of Chicago
characterized 42 Flublok-induced monoclonal antibodiesand 38 Flucelvax-induced
mAbs for avidity, cross reactivity, and any selectivity towards the head versus
the stalk domain to compare the fine specificity of the antibodies induced by recombinant
hemagglutinin vaccine produced in insect cells (Flublok) and Flucelvax,
prepared from virions produced in mammalian cells.
Similarly, in August 2019,
researchers from Icahn School of Medicine at Mount Sinai characterized
monoclonal antibodies isolated from a patient with an active Zika virus
infection that potently neutralized virus infection in Vero cells at the
nanogram-per-milliliter range.
In June 2018, researchers from
Bristol-Myers Squibb reported that 6200_A08, a novel gp41-binding Adnectin with
potent anti-HIV activity is highly synergistic when linked to a CD4-binding
Adnectin. Novel bispecific molecules of this type may serve as the next
generation of potent antiviral agents.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/43
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
No comments:
Post a Comment